Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
In previous communications we have demonstrated that crude rat interleukin 2 and partially purified mouse interleukin 2 were capable of inhibiting growth of transplantable, MC-induced mouse sarcomas in syngeneic recipients. Here we report that repeated peritumoral injections of highly purified human recombinant interleukin 2 can inhibit growth of these mouse sarcomas and prolong survival of tumour-bearing mice. These findings taken together and the ready availability of high doses of recombinant human interleukin 2 substantiate our proposal for initiation of clinical trials using local administration of the interleukin 2 (Bubeník et al. 1983) in selected cancer patients.
D000818:Animals; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology* / Q000302:isolation & purification; D008748:Methylcholanthrene; D051379:Mice; D008815:Mice, Inbred Strains; D012513:Sarcoma, Experimental / Q000139:chemically induced / Q000628:therapy*
D007376:Interleukin-2; D008748:Methylcholanthrene